BTK inhibitor + PD1 inhibitor + XPO1 inhibitor

This is a combination therapy consisting of three distinct classes of targeted agents: - A Bruton's tyrosine kinase (BTK) inhibitor, which blocks BTK signaling critical for B-cell receptor pathway activation and survival in B-cell malignancies. - A programmed cell death protein 1 (PD1) inhibitor, an immune checkpoint blocker that enhances T-cell mediated anti-tumor immunity by preventing the inhibition of T-cells by tumor cells. - An exportin 1 (XPO1) inhibitor, which blocks nuclear export of tumor suppressor proteins and growth regulatory proteins, leading to cancer cell apoptosis. This triple combination is being explored as a potential treatment strategy for hematologic malignancies such as diffuse large B-cell lymphoma (DLBCL), primary central nervous system lymphoma (PCNSL), and other cancers where resistance to single-agent therapies is common. The rationale for this combination includes overcoming resistance mechanisms seen with BTK inhibitors alone and leveraging synergistic effects on both malignant cells and the tumor microenvironment[2][3][1].